Abstract | PURPOSE: CASE REPORT: Intravitreal bevacizumab injection was given in a patient with neovascular glaucoma and the changes in the visual acuity, intraocular pressure (lOP), iris neovascularisation were noted before injection and after one day, one week, three weeks and six weeks. Regression of the iris new vessels and normalization of the intraocular pressure was noted. CONCLUSION:
|
Authors | A S Kelkar, S B Kelkar, J A Kelkar, M Nagpal, S P Patil |
Journal | Bulletin de la Societe belge d'ophtalmologie
(Bull Soc Belge Ophtalmol)
Issue 303
Pg. 43-5
( 2007)
ISSN: 0081-0746 [Print] Belgium |
PMID | 17894286
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Bevacizumab
|
Topics |
- Aged
- Angiogenesis Inhibitors
(administration & dosage)
- Antibodies, Monoclonal
(administration & dosage)
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Diabetes Mellitus, Type 2
(complications)
- Glaucoma, Neovascular
(drug therapy, etiology)
- Humans
- Hypertension
(complications)
- Male
- Remission Induction
|